Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." ?g. }

• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _5 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _5 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.
• _4 value "Several experimental evidences point to the possibility that FGF2 induces neovascularization indirectly by activation of the VEGF/ VEGFR system. Indeed: (i) VEGFR-2 antagonists inhibit both VEGF and FGF2-induced angiogenesis in vitro and in vivo [98]; (ii) expression of dominant-negative FGFR1 or FGFR2 in glioma cells results in a decrease in tumor vascularization paralleled by VEGF down-regulation [99]; (iii) both endogenous and exogenous FGF2 modulate VEGF expression in endothelial cells [82]; (iv) in the mouse cornea, the quiescent endothelium of vessels of the limbus express both VEGF mRNA and protein only after FGF2 treatment. In the same model, systemic administration of anti-VEGF-A neutralizing antibodies dramatically reduces FGF2-induced vascularization [82]; (v) VEGFR-1-blocking antibodies or the expression of a dominant-negative VEGFR-1 result in a significant reduction of FGF2-induced cell extensions and capillary morphogenesis [56]; (vi) FGF2 upregulates the expression of both FGFRs and VEGFRs in endothelial cells [100]." provenance.